ArticleNature reviews. Microbiology2013
Development of vaccines for Candida albicans: fighting a skilled transformer.
Article in Nature reviews. Microbiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Abundant Yet Aberrant T Helper Cell Responses to Candida albicans Underlie Mucosal Candidiasis in Humans and Mice.European journal of immunology · 2025Article
- New antifungal strategies and drug development against WHO critical priority fungal pathogens.Frontiers in cellular and infection microbiology · 2025Review
- Toll-like receptor 4 (TLR4) is the major pattern recognition receptor triggering the protective effect of amSphere · 2024Article
- Combinatorial actions of IL-22 and IL-17 drive optimal immunity to oral candidiasis through SPRRs.PLoS pathogens · 2024Article
- Exploring the effects of culture conditions on Yapsin (Open life sciences · 2024Article
- Advancing Vaccine Strategies againstVaccines · 2023Review
- Construction ofVaccines · 2023Article
- Targeting Virulence Factors ofFoods (Basel, Switzerland) · 2022Review
- Systemic Infection by Non-Journal of fungi (Basel, Switzerland) · 2022Article
- Vaccines for human fungal diseases: close but still a long way to go.NPJ vaccines · 2021Review
- Genetic Vaccination as a Flexible Tool to Overcome the Immunological Complexity of Invasive Fungal Infections.Frontiers in microbiology · 2021Review
- It Takes Two to Tango: How a Dysregulation of the Innate Immunity, Coupled WithFrontiers in microbiology · 2021Review
- Protective effect of fungal extracellular vesicles against murine candidiasis.Cellular microbiology · 2020Article
- Vaccination with Secreted Aspartyl Proteinase 2 Protein fromInfection and immunity · 2020Article
- Moonlighting Proteins at the Candidal Cell Surface.Microorganisms · 2020Review
- Oral epithelial IL-22/STAT3 signaling licenses IL-17-mediated immunity to oral mucosal candidiasis.Science immunology · 2020Article
- Regulation of host-microbe interactions at oral mucosal barriers by type 17 immunity.Science immunology · 2020Review
- 11g, a Potent Antifungal Candidate, EnhancesFrontiers in microbiology · 2020Article
- Carbohydrate Conjugates in Vaccine Developments.Frontiers in chemistry · 2020Review
- Dok3-protein phosphatase 1 interaction attenuates Card9 signaling and neutrophil-dependent antifungal immunity.The Journal of clinical investigation · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two univalent subunit vaccines that are based on major virulence traits of Candida albicans have completed Phase I clinical trials in recent years. Although it is hoped that at least one will become the first antifungal vaccine approved for human use, there are some major obstacles to achieving this. The difficulties mostly arise from the remarkable ability of C. albicans to deceive the host immune system. In this Opinion article, I argue that the development of a multivalent vaccine that induces an immune response against multiple, unrelated virulence traits of this human commensal fungus and opportunistic pathogen may be a better approach.
Indexed as
Identifiers
24232568What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.